Monitor outcome of the FDA meeting as it will determine whether the BLA for ONS-5010/LYTENAVA will be approved, which is critical for this small-cap biotech's future revenue potential.
Price Chart
Executive Summary
Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete Response Letter for its ONS-5010/LYTENAVA biologics license application, and the FDA has accepted the request and granted a meeting with the deciding official. This is a procedural step in the regulatory review process for a drug that was previously not approved.
Key Facts
- Company submitted a Formal Dispute Resolution Request (FDRR) to the FDA regarding a December 30, 2025 Complete Response Letter (CRL) for ONS-5010/LYTENAVA
- FDA accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026
- The BLA concerns ONS-5010/LYTENAVA for treatment of neovascular age-related macular degeneration
- Company believes existing clinical data from NORSE TWO and NORSE EIGHT trials support approval
Financial Impact
No immediate financial impact disclosed; outcome of FDA dispute resolution will determine future commercial potential
Risk Factors
- FDA may uphold its Complete Response Letter and deny approval
- Further delays or requests for additional clinical data could increase development costs
- Competitive risks if rival treatments gain market share during approval delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040387 |
| Document: tm2611268d1_ex99-1.htm | 0001104659-26-040387 |
| Document: 0001104659-26-040387-index-headers.html | 0001104659-26-040387 |
| Document: 0001104659-26-040387-index.html | 0001104659-26-040387 |
| Document: 0001104659-26-040387.txt | 0001104659-26-040387 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access